One cupcake won't kill you', 'I'm going to get diabetes just looking at that', 'That person doesn't look like they have ...

Abbott (NYSE:ABT) is launching a new initiative that takes a look at some of the stigmas and stereotypes that come with ...

Abbott (NYSE:ABT) is launching a new initiative that takes a look at some of the stigmas and stereotypes that come with ...

The FreeStyle Libre 3 system helped Nathan manage his diabetes. Now, he's sharing his story to help lift stigma.Abbott NORTHAMPTON, MA / ACCESS Newswire / February 7, 2025 / As a competitive powerlift ...

Abbott has launched Above the Bias, a global initiative to drive awareness about the health impact that common misconceptions and bias about diabetes can have on people living with ...

The CGM business is among the top growth drivers in Abbott’s medical devices business, with diabetes care posting 19% organic sales growth for the first nine months of 2024, Abbott said in a ...

The company's Q3 profir increased 16 per cent year-on-year (Y-o-Y) to Rs 360.78 crore as compared to Rs 310.98 crore ...

Abbott Laboratories (NYSE: NYSE:ABT) has demonstrated resilience and growth potential in the healthcare sector, maintaining a strong financial profile despite facing various challenges. According to ...

general manager of Abbott's UK and Ireland diabetes care business. In clinical trials, use of the Freestyle Libre CGM range has been shown to improve blood glucose control, reducing hypoglycaemic ...

Investors feel optimistic about Abbott's robust strength in the Core Diagnostics business. Yet, unfavorable forex impacts are concerning.